Blockade of AT1R was explored in animal models and in clinical studies in order to develop therapeutic strategies to reduce liver fibrosis (Munshi et al. 2011) and cholestasis (Patel 2003; Paizis et al. 2002). This evidence concerns the gene AGTR1 and cholestasis.